ENTRESTO HF Meeting Invite

INVITATION Tuesday 4th October 2022, 6 pm Treating Heart Failure in Primary Care .....What do I do next?

Speakers: Dr Calum Young - Cardiologist Rachel Hall - Nurse Practitioner, Cardiology You are invited to attend a Novartis-sponsored educational Dinner meeting on Tuesday 4th October starting at 6pm. The meeting will be held at Trinity Wharf Tauranga The aims of the meeting are to: • Outline the heart failure treatments available to General Practice • Provide practical tips on initiation, titration, and recommended ongoing follow up • Provide an opportunity for primary and secondary care to share information on how to best care for patients

Agenda Time 5:45 pm 6:10 pm 6:30 - 7:15 7:20 – 7:50 8 pm

Session Registration and welcome drink Dinner served Managing Heart Failure in General Practice A practical approach when managing patients, insights from a NP. Meeting Close

Speaker

Dr Calum Young Rachel Hall, NP

I hope you are able to attend this interesting and interactive meeting. Please don’t hesitate to call me directly if you have any questions.

Kind regards, Anita Timms Key Account Manager Novartis To register , please return the following form to anita.timms@novartis.com or fax 021 639955 64 9 361 8181 before 20th September <Insert mobile number>

RSVP Please return to anita.timms@novartis.com or fax 64 9 361 8181 before Tuesday 20th Sept You will receive confirmation of your registration to your email address Numbers are limited Doctor / Nurse name/s Surgery name Email address Phone number ( required in case of changes to meeting)

Dietary requirements Signature I have read and understood the privacy notice and hereby consent to it - please tick.

By providing your personal information to Novartis New Zealand Limited or its related bodies corporate (Novartis), you consent to Novartis collecting, storing and using your personal information in accordance with the Novartis Privacy Policy.

In particular, you consent to Novartis using your personal information to communicate with you about Novartis products and/or to support your use of those products, and you consent to Novartis using your personal information for audit or inspection purposes. Novartis reserves the right to use aggregated and de-identified data collected through this activity.

You also consent to Novartis using your personal information to (where applicable) invite you to, or arrange your participation in, activities managed by (or on behalf of) Novartis. Novartis is committed to patient safety. In accordance with regulatory obligations Novartis processes reports of adverse events experienced by patients taking a Novartis product, when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other Pharmaceutical companies with whom Novartis has a license agreement and third parties we work with for the purpose of safety reporting. Your information may be stored on servers located in jurisdictions outside of New Zealand, such as Switzerland, United Kingdom, United States of America and others. Some of those countries may not offer the same level of privacy protection as in New Zealand. However, Novartis will enter into agreements with its third-party service providers to keep your information secure and provide adequate protection for your data. You are not obliged to provide personal information. However, if you do not provide information you may not, for example, be able to participate fully in activities managed by us. You have the right to access, update or correct your personal information and/or decline to receive communications from Novartis. To find out how, please refer to our Privacy Policy or contact our Privacy Officer at Novartis New Zealand Ltd, PO Box 99102 Newmarket Auckland 1023, New Zealand. Phone: +64 9 361 8100 Email:privacy.au@novartis.com.

PRESCRIPTION MEDICINE. Entresto® 24mg/26mg, 49mg/51mg, 97mg/103mg (sacubitril/valsartan) film coated tablets.

Consult full Data Sheet before prescribing, for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at www.medsafe.govt.nz. Entresto is a fully funded medicine under special authority – please consult www.pharmac.govt.nz. Entresto is a registered trademark of Novartis AG, Switzerland. Novartis New Zealand Limited, Auckland. Ph 0800 652 422 NZ-00760 June 2020, TAPs NA12071 BGA200610